Phase i dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 2, 2009, Pages 253-260

  Kim, Yeul Hong ^a   Seo, Hee Yeon ^a   Jeen, Yoon Tae ^a   Kim, Hoon Kyo ^b   Shim, Byoung Yong ^b   Yang, Jinmo ^b  

^a Korea University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Clinical trial; Combination chemotherapy; Docetaxel; Gastric neoplasm; Phase I; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; FLUOROURACIL; MITOMYCIN; PEMETREXED; TS 1; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION; LEUKOPENIA; LIVER FUNCTION; MALE; MAXIMUM TOLERATED DOSE; METABOLIC ACIDOSIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OXONIC ACID; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR; TREATMENT OUTCOME;

EID: 57149129932     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0734-6     Document Type: Article

References (32)

1. F Kamangar GM Dores WF Anderson 2006 Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2137 2150
2. R Pazdur AP Kudelka JJ Kavanagh PR Cohen MN Raber 1993 The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere) Cancer Treat Rev 19 351 386
3. JF Diaz JM Andreu 1993 Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition Biochemistry 32 2747 2755
4. S Di Cosimo G Ferretti N Fazio N Silvestris P Carlini A Alimonti A Gelibter A Felici P Papaldo F Cognetti 2003 Docetaxel in advanced gastric cancer-review of the main clinical trials Acta Oncol 42 693 700
5. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni A Rodrigues M Fodor Y Chao E Voznyi ML Risse JA Ajani 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991 4997
6. T Shirasaka Y Shimamato H Ohshimo M Yamaguchi T Kato K Yonekura M Fukushima 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 557
7. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720
8. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191 197
9. P Chollet P Schoffski K Weigang-Kohler JH Schellens H Cure N Pavlidis V Grunwald R De Boer J Wanders P Fumoleau 2003 Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG) Eur J Cancer 39 1264 1270
10. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Kimura A, Ohtsu A, Group GOSGJCO (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol. ASCO Annual Meeting Proceedings Part I., Chicago, pp 200S, Abstract No. LBA4513
11. Narahara H, Koizumi W, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, TrialGroup T-AGCAC (2007) Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. J Clin Oncol. ASCO Annual Meeting Proceedings Part I., Chicago, pp 201S, Abstract No. 4514
12. S Sakuramoto M Sasako T Yamaguchi T Kinoshita M Fujii A Nashimoto H Furukawa T Nakajima Y Ohashi H Imamura M Higashino Y Yamamura A Kurita K Arai 2007 Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810 1820
13. I Takahashi Y Emi Y Kakeji J Uchida M Fukushima Y Maehara 2005 Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts Oncology 68 130 137
14. Y Wada K Yoshida T Suzuki H Mizuiri K Konishi K Ukon K Tanabe Y Sakata M Fukushima 2006 Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines Int J Cancer 119 783 791
15. Y Rino Y Takanashi N Yukawa H Saeki H Wada M Kanari R Yamada T Satoh N Yamamoto T Imada 2006 A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer Anticancer Res 26 1455 1462
16. I Takahashi Y Emi Y Kakeji E Tokunaga S Ushiro E Oki M Watanabe H Baba Y Maehara 2006 Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer Oncol Rep 15 849 854
17. K Yamaguchi T Shimamura I Hyodo W Koizumi T Doi H Narahara Y Komatsu T Kato S Saitoh T Akiya M Munakata Y Miyata Y Maeda H Takiuchi S Nakano T Esaki F Kinjo Y Sakata 2006 Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer Br J Cancer 94 1803 1808
18. K Yoshida N Hirabayashi W Takiyama M Ninomiya N Takakura J Sakamoto M Nishiyama T Toge 2004 Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer Anticancer Res 24 1843 1851
19. K Yoshida M Ninomiya N Takakura N Hirabayashi W Takiyama Y Sato S Todo M Terashima M Gotoh J Sakamoto M Nishiyama 2006 Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer Clin Cancer Res 12 3402 3407
20. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
21. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer treatment Cancer 47 207 214
22. GJ Peters P Noordhuis AB Van Kuilenburg JH Schornagel H Gall SL Turner MS Swart D Voorn AH Van Gennip J Wanders U Holwerda K Smid G Giaccone P Fumoleau CJ Van Groeningen 2003 Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2, 4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors Cancer Chemother Pharmacol 52 1 12
23. A Sulkes J Smyth C Sessa LY Dirix JB Vermorken S Kaye J Wanders H Franklin N LeBail J Verweij 1994 Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group Br J Cancer 70 380 383
24. AI Einzig D Neuberg SC Remick DD Karp PJ O'Dwyer JA Stewart AB Benson 3rd 1996 Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293 Med Oncol 13 87 93
25. F Giuliani V Gebbia F De Vita E Maiello M Di Bisceglie G Catalano N Gebbia G Colucci 2003 Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.) Anticancer Res 23 4219 4222
26. D Mavroudis C Kourousis N Androulakis K Kalbakis S Agelaki S Kakolyris J Souglakos E Sarra N Vardakis D Hatzidaki G Sarmonis V Georgoulias 2000 Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial Am J Clin Oncol 23 341 344
27. M Mai Y Sakata R Kanamaru M Kurihara M Suminaga J Ota N Hirabayashi T Taguchi H Furue 1999 [A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B]) Gan To Kagaku Ryoho 26 487 496
28. T Taguchi Y Sakata R Kanamaru M Kurihara M Suminaga J Ota N Hirabayashi 1998 [Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)] Gan To Kagaku Ryoho 25 1915 1924
29. YJ Bang WK Kang YK Kang HC Kim C Jacques E Zuber B Daglish Y Boudraa WS Kim DS Heo NK Kim 2002 Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial Jpn J Clin Oncol 32 248 254
30. JH Chun HK Kim JS Lee JY Choi B Hwangbo HG Lee SR Park IJ Choi CG Kim KW Ryu YW Kim JS Lee JM Bae 2005 Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer Am J Clin Oncol 28 188 194
31. JG Kim SK Sohn DH Kim JH Baek WJ Sung JY Park TB Kim HY Jung W Yu KB Lee 2005 Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer Oncology 68 190 195
32. YH Park BY Ryoo SJ Choi HT Kim 2004 A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer Br J Cancer 90 1329 1333